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Interleukin (IL)-18 is produced by leukocytes and renal
parenchymal cells (tubular epithelial cells, podocytes, and
mesangial cells). The IL-18 receptor (IL-18R) is expressed on
these cells in cisplatin-induced acute kidney injury, but the
role of IL-18R is unknown. To help define this, we compared
IL-18Ra knockout with wild-type mice in cisplatin-induced
acute kidney injury and found deteriorated kidney function,
tubular damage, increased accumulation of leukocytes
(CD4þ and CD8þ T-cells, macrophages, and neutrophils),
upregulation of early kidney injury biomarkers (serum TNF,
urinary IL-18, and KIM-1 levels), and increased expression of
pro-inflammatory molecules downstream of IL-18. In vitro,
leukocytes from the spleen and kidneys of the knockout mice
produced greater amounts of pro-inflammatory cytokines
upon stimulation with concanavalin A compared to that in
wild-type mice. Levels of the suppressor of cytokine signaling
1 and 3 (negative regulators of cytokine signaling) were
reduced in the spleen and kidneys of IL-18Ra-deficient
compared to wild-type mice. Adoptive transfer of wild-type
splenocytes by IL-18Ra-deficient mice led to decreased
cisplatin nephrotoxicity compared to control IL-18Ra-
deficient mice. In contrast, anti-IL-18Ra and anti-IL-18Rb
antibody treatment tended to increase cisplatin
nephrotoxicity in wild-type mice. Thus, signaling through
IL-18Ra activates both inflammation-suppressing and
pro-injury pathways in cisplatin-induced acute kidney injury.
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Cisplatin is widely used to treat carcinoma patients. How-
ever, the drug’s use is limited because of its side effects in
normal tissues, particularly injury to the kidneys.1 The main
site of cisplatin action is in proximal tubule epithelial cells.
Although tubular epithelial cell death is recognized as a major
determinant of cisplatin nephrotoxicity, it remains unclear
how these cells are terminally injured under the inflamma-
tory mechanism. In animals, the in vivo use of cisplatin
induces both necrosis and apoptosis in renal tubules.2 In the
kidney, interleukin (IL)-18 is a sensitive and early marker
of renal tubular damage,3 and in animal models of renal
ischemia–reperfusion injury, IL-18 exacerbates acute tubular
necrosis.4 IL-18 is known as an interferon (IFN)-g-inducing
factor because of its ability to induce IFN-g production in
T cells and NK cells. It is synthesized as a biologically inactive
precursor (pro-IL-18), similar to IL-1b, which requires
cleavage into an active molecule by an intracellular cysteine
protease or caspase-1. IL-1b-converting enzyme (caspase-1)
cleaves the pro-IL-18 to make a bioactive mature form of
IL-18 that recognizes a heterodimeric receptor, which consists
of unique a (IL-1 receptor (R)-accessory protein-like)
signaling chains and nonbinding b (IL-1R-accessory protein-
like) signaling chains.5 In dextran sodium sulfate-induced
colitis, neutralizing antibodies to IL-18 or IL-18-binding
protein ameliorate the disease,6,7 whereas in other studies,
mice deficient in IL-18Ra exhibit worsening of the disease.8
In addition to rejecting insulin-producing islet allografts,
splenocytes and peritoneal macrophages from IL-18Ra-
deficient mice produced significantly greater amounts of
several pro-inflammatory cytokines on stimulation with
concanavalin A (ConA).9
In this study, we investigated the paradoxical findings of
the effect of IL-18R on cytokine production to determine
whether knocking out and blocking IL-18R would aggravate
or ameliorate cisplatin-induced nephrotoxicity. We found
that IL-18Ra-deficient mice had markedly deteriorated renal
function and increased histologic injury when they were
exposed to cisplatin. The adoptive transfer of splenocytes
from wild-type (WT) mice into IL-18Ra-deficient mice
decreased cisplatin nephrotoxicity. In contrast, with the
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anti-IL-18Ra and anti-IL-18Rb administration, the nephro-
toxicity tended to deteriorate. Renal pro-inflammatory
cytokines were increased in IL-18Ra-deficient mice when
compared with those in WT mice. The results indicated that
IL-18Ra has an inflammation-suppressing signal by a sup-
pressors of cytokine signaling (SOCS) pathway in cisplatin-
induced acute kidney injury (AKI).
RESULTS
Functional, structural aggravation from cisplatin
nephrotoxicity
Kidneys in IL-18Ra-deficient and WT mice showed normal
morphology on day 1 (Figure 1a and c). On day 3, IL-18Ra-
deficient mice developed severe tubular injury with cast
formation, loss of brush border membranes, sloughing of
tubular epithelial cells, and dilation of tubules (Figure 1d).
In WT mice, the damage on day 3 was limited to mild
swelling of the tubular epithelial cells, and less histological
damage was visible (Figure 1b). Semiquantitative injury
scoring in the two groups showed significantly increased
necrosis scores between days 1 and 3, respectively, reflecting
significant kidney injury. On day 1, the necrosis score was the
same in the two groups. On day 3, the necrosis score in
IL-18Ra-deficient mice was increased significantly compared
with that in WT mice (Figure 1e). The cisplatin-induced rise
in blood urea nitrogen (BUN) and serum creatinine levels at
day 3 was also significantly increased in IL-18Ra-deficient
mice compared with that in WT mice (Figure 2a).
Serum and urinary biomarker in renal injury
Serum tumor necrosis factor (TNF) and IL-18 production
(Figure 2b) and urinary IL-18 and Kim-1 (Figure 2c) were
measured as biomarkers in AKI. Serum TNF was not detected
in IL-18Ra-deficient mice or WT mice on day 1 (limit of
detection of enzyme-linked immunosorbent assay 20 pg/ml).
TNF in IL-18Ra-deficient mice was increased significantly on
day 3. Serum IL-18 was not detected in mice of either group
on day 1 (limit of detection of enzyme-linked immunosor-
bent assay 15.6 pg/ml). Serum IL-18 in mice of either group
was increased significantly on day 3 compared with that on
day 1. However, serum IL-18 was the same level in the two
groups.
We also investigated urinary IL-18 and Kim-1 levels as
predictors in cisplatin-induced AKI. Urinary IL-18 levels on
day 1 were not detected in any mice, whereas urinary IL-18
levels in IL-18Ra-deficient mice on day 3 were increased
significantly compared with those in WT mice. Urinary Kim-
1 levels on day 1 were the same in the two groups, however,
Kim-1 levels in IL-18Ra-deficient mice were increased
significantly compared with those in WT mice by day 3.
The infiltration of CD4þ and CD8þ T cells, macrophages,
and neutrophils in cisplatin-induced renal injury
We investigated the infiltration of inflammation cells, that is,
CD4þ and CD8þ T cells, macrophages, and neutrophils, in
the renal interstitium on days 1 and 3 (Figure 3). Interstitial
CD4þ T-cell numbers in IL-18Ra-deficient mice on day 1
showed increased significantly compared those in WT mice.
In contrast, interstitial CD8þ T cells infiltrating the renal
interstitium were increased significantly in IL-18Ra-deficient
mice on day 3 compared with WT mice. Interstitial
macrophage and neutrophil infiltrate shows the greatest
increase in cisplatin injected by day 3. In IL-18Ra-deficient
mice, macrophage numbers were not significantly increased
on day 1. On day 3, the time of peak infiltration in WT mice,
renal macrophage, and neutrophil numbers were increased
significantly in IL-18Ra-deficient mice.
Cisplatin-induced phospho nuclear factor (NF)-jB p65
activation and apoptosis
Figure 4 shows the effect of IL-18Ra on phospho NF-kB p65
as a marker of NF-kB activation and cleaved caspase-3 as a
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Figure 1 |Representative light microscopy of periodic acid-
Schiff (PAS)–stained renal sections after cisplatin injection.
Kidneys in wild-type (WT) (a, day 1 and b, day 3 after cisplatin
injection) and interleukin-18 receptor (IL-18R)a-deficient (IL-18Ra
knockout (KO); c, day 1 and d, day 3) mice were showed. Tubular
necrosis (e) was scored in the outer medulla of the kidney (see the
‘Materials and Methods’ section for the scoring method), the
panels are shown as mean score±s.e. (wPo0.05, the necrosis
score on day 1 vs. 3 and *Po0.05, the necrosis score in WT and
IL-18Ra KO mice on day 3). Original magnifications  400. Scale
bar, 50mm. ATN, acute tubular necrosis.
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marker of apoptosis. These markers showed increased
expression in tubules after cisplatin injection. In IL-18Ra-
deficient mice, nuclear staining of p65-positive cells was
increased significantly in tubules on days 1 and 3 (Figure 4a
and b, respectively). Cleaved caspase-3 on day 1 was not
detected in either group. In IL-18Ra-deficient mice, cleaved
caspase-3 in tubules was significantly increased on day 3
(Figure 4c and d).
Renal mRNA expression in cisplatin-induced renal injury
Renal mRNA was measured by real-time quantitative PCR, as
described in the Materials and Methods section. It is well
documented that inflammatory cytokine and chemokine
release contribute to cisplatin nephrotoxicity.10 Figure 5
shows that cisplatin upregulated the pro-inflammatory
cytokine expression of IL-1b, IL-12p40, and IL-18
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Figure 2 | Effect of interleukin-18 receptor (IL-18R)a on blood
urea nitrogen, serum creatinine, serum cytokines, and urinary
biomarkers. Blood samples were collected on day 1 and day 3
after cisplatin injection, then blood urea nitrogen (BUN) and
serum creatinine were measured (a). Dotted lines represent mean
values from saline-treated mice without cisplatin. Serum tumor
necrosis factor (TNF) and interleukin (IL)-18 (b), urinary IL-18 and
Kim-1 (c) were measured as early biomarker in acute kidney injury
on days 1 and 3. Serum TNF and IL-18, and urinary IL-18 were not
detected on day 1, the panels are shown as mean values±s.e.
(*Po0.05, wild-type (WT) vs. IL-18 receptor (IL-18R)a knockout
(KO) mice on day 3, wPo0.05, WT and IL-18Ra KO mice on day 1
vs. WT and IL-18Ra KO mice on day 3). ND, not determined; sCr,
serum creatinine.
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Figure 3 | Interstitial accumulation of leukocytes after
cisplatin injection in wild-type (WT) and interleukin-18
receptor (IL-18R)a-deficient (IL-18Ra knockout (KO)) on days 1
and 3. The panels are shown as mean numbers±s.e (c/10hpf, cell
numbers per 10 high-power field), (*Po0.05, the cell numbers in
WT vs. IL-18Ra KO mice on days 1 and 3).
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Figure 4 | Effect of interleukin-18 receptor (IL-18R)a on
phospho nuclear factor (NF)-jB p65 and cleaved caspase-3 in
cisplatin-induced acute kidney injury (AKI) on days 1 and 3.
Representative photograph and the scale graph of positive
tubule cells (10 fields at  400 magnification) expressing phospho
NF-kB p65 (a, b, black arrow) and cleaved caspase-3
(c, d, white arrow) in IL-18Ra-deficient and wild-type (WT) mice on
day 3 were shown. Semiquantitative score of positive cells in renal
tissue, the panels are shown as mean numbers±s.e. Original
magnifications  400 (*Po0.05, **Po0.01, and ***Po0.005,
positive tubule cells in WT vs. IL-18Ra-deficient mice on days 1
and 3). Scale bar, 50 mm. c/10hpf, cell numbers per 10 high-power
field; ND, not determined.
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significantly in IL-18Ra-deficient mice. IL-10, TNF, and IFN-
g mRNA cytokine and mRNA chemokine expression of
monocyte chemoattractant protein-1 increased after cisplatin
injection compared with the expression in WT mice.
Renal and urinary Kim-1 expression
Figure 6 shows tubular Kim-1 expression after cisplatin
injection. In WT mice, Kim-1 were not detected in the kidney
on day 1 (Figure 6a). However, there were more of these cells
in tubules on day 3 (Figure 6b). In IL-18Ra-deficient mice, a
trace amount of Kim-1 was present on day 1 (Figure 6c, black
arrow). The number of Kim-1 was dramatically increased on
day 3 compared with that on day 1 (Figure 6d). The numbers
of Kim-1 in IL-18Ra-deficient mice were increased signi-
ficantly on day 3 compared with that on day 1 (Figure 6e).
The difference in the number of Kim-1 between the groups
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Figure 5 | Effects of interleukin-18 receptor (IL-18R) on gene expression in the kidney. Cytokine and chemokine gene expression was
measured 1 and 3 days after cisplatin injection in wild-type (WT) mice and IL-18Ra-deficient (IL-18Ra knockout (KO)) mice by real-time
reverse transcriptase (RT)-PCR. In each experiment, the expression levels were normalized to the expression of 18SrRNA and are expressed
relative to saline-treated control mice, the panels are shown as mean fold-increase±s.e. (*Po0.05, **Po0.01, and ***Po0.005, WT vs.
IL-18Ra KO mice on days 1 and 3). CCL2/MCP-1, monocyte chemoattractant protein-1; IFN, interferon; ND, not determined; TNF, tumor
necrosis factor.
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was significantly greater on day 3 than on day 1. We also
investigated Kim-1 mRNA expression on days 1 and 3 and
found that the expression in IL-18Ra-deficient mice was
increased significantly from days 1 to 3 (Figure 6f).
Apoptosis and activation in cisplatin-induced renal injury
We analyzed apoptosis and activation of splenic and renal
CD4þ and CD8þ T cells by flow cytometric analysis (FACS),
as shown in Figure 7. Apoptosis of CD4þ and CD8þ T cells
from the spleen and kidney was significantly increased in
IL-18Ra-deficient mice on day 1 (Figure 7a). Activation of
CD44 as the cell surface expression of an activation marker
on CD4þ T cells was the same in IL-18Ra-deficient and
WT mice. However, CD44 on CD8þ T cells was significantly
increased in IL-18Ra-deficient mice on day 1 (Figure 7b).
Furthermore, activation of CD69 as an early activation marker
on CD4þ and CD8þ T cell was significantly increased in
IL-18Ra-deficient mice on day 3 (Figure 7c).
SOCS1 and SOCS3 expression in cisplatin-induced renal
injury
Figure 8 shows renal mRNA and protein levels of SOCS1 and
SOCS3 in WT and IL-18Ra-deficient mice on day 3 by real-
time PCR (Figure 8a) and western blotting (Figure 8b and c).
Renal SOCS1 and SOCS3 mRNA in IL-18Ra-deficient mice
was decreased significantly compared with that in WT mice.
Protein levels of splenic and renal SOCS3 in IL-18Ra-
deficient mice were also significantly reduced compared with
those in WT mice. Protein SOCS1 was not detected.
Proliferative response and cytokine production in vitro
Figure 9a and b show the proliferation and cytokine pro-
duction by leukocytes in the spleen and kidney with ConA
for 4 and 48 h. Splenic and renal leukocytes proliferation in
IL-18Ra-deficient mice was increased for 4 h. IFN-g, TNF,
and IL-12p40 levels of splenocytes and/or renal leukocytes in
IL-18Ra-deficient mice were increased significantly compared
with those in WT mice. IL-10 level was the same in the two
groups. IL-1b and IL-18 could not be detected. Figure 9c
shows IFN-g intracellular staining of CD4 and CD8þ T cells
in the spleen and kidney by FACS. IFN-g-producing splenic
CD4þ cells were the same in the two groups. However, the
number of IFN-g-producing splenic CD8þ cells in IL-18Ra-
deficient mice was increased significantly compared with the
number in WT mice.
Splenocytes adoptive transfer reconstituted kidney
susceptibility to cisplatin nephrotoxicity
To determine whether IL-18Ra deficiency was indeed an
exacerbating factor in cisplatin-induced AKI, we transferred
5 106 splenocytes from normal WT mice into each of five
IL-18Ra-deficient mice. The successful transfer of splenocytes
was confirmed by FACS analysis with IL-18R staining. The
mean population of T cells in the WT mouse spleen was 5.1%
of total splenocytes. Meanwhile, IL-18Ra-deficient mice had
minimal 1.7% splenocytes. Three weeks after the transfer, the
splenocytes in IL-18Ra-deficient mice were reconstituted to
3.4%, which was 50% of the level in WT mice. Splenocyte
transfers led to a significant improvement of renal dysfunction
in IL-18Ra-deficient mice. There was a significant improve-
ment in BUN and acute tubular necrosis score in IL-18Ra-
deficient mice that received a transfer of splenocytes when
compared with IL-18Ra-deficient mice without transfer on
day 3 after cisplatin injection (Figure 10). In Supplementary
Figure S1 online, renal pro-inflammatory cytokines and che-
mokines expression were trend to increase and increased sig-
nificantly in IL-18Ra-deficient mice compared with those in
the mice received a transfer of splenocytes and WT mice. In
the contract, renal SOCS1 and SOCS3 expression were decreased
significantly in IL-18Ra-deficient mice and the mice received
a transfer of splenocytes compared with WT mice.
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Figure 6 | Expression of Kim-1 in the kidney. Representative
photograph of Kim-1 expression in the kidney after cisplatin
injection (a–d). In wild-type (WT) mice, Kim-1-positive cells were
not detected in the kidney on day 1 (a). On day 3, Kim-1-positive
cells were present at the apical membrane (b). In interleukin-18
receptor (IL-18R)a-deficient (IL-18Ra knockout (KO)) mice, a trace
amount of Kim-1-positive cells is present on day 1 (c, arrow). On
day 3, Kim-1-positive cells were progressively increased (d). The
number of Kim-1-positive cells in 10 400 fields (e). Expression of
renal Kim-1 mRNA were showed on days 1 and 3 (f). The panels
are shown as mean numbers and fold increase±s.e. (*Po0.05,
WT vs. IL-18Ra-deficient mice on days 1 and 3, wPo0.05, WT and
IL-18Ra knockout (KO) mice on day 1 vs. WT and IL-18Ra KO mice
on day 3). Scale bar, 50mm. c/10hpf, cell numbers per 10
high-power field.
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Blocking the signaling pathway by anti-IL-18Ra and
anti-IL-18Rb antibody administration
To determine whether blocking the IL-18Ra and IL-18Rb
signaling pathway could contribute to deteriorated renal
function, we administrated IL-18Ra and IL-18Rb antibody to
WT mice in cisplatin-induced renal injury. These mice
showed deteriorated BUN compared with the mice given rat
immunoglobulin G (Figure 11). In Supplementary Figure S2
online, renal pro-inflammatory cytokines and chemokines
expression were increased in the mice given IL-18Ra and IL-
18Rb antibody compared with those in control mice. Renal
SOCS1 and SOCS3 expression were decreased significantly in
the mice given IL-18Ra and IL-18Rb antibody compared
with those in control mice.
DISCUSSION
We previously reported that MRL/lpr mice cross-bred with
mice deficient in IL-18Ra exhibited a reduction in auto-
antibodies, nephritis, and death.11 However, in some studies,
paradoxical findings were reported in IL-18.8,9 In this study,
we demonstrated that inflammatory cells were increased in
the kidney and deteriorated the renal function in IL-18Ra-
deficient mice. One of our goals was to determine the
mechanism of action of IL-18Ra activation and signaling in
AKI. The development of cisplatin-induced AKI in WT mice
is dependent on the infiltration of activated CD4þ T cells in
the kidney, an event that is accompanied by the influx of
other immune cells, including CD8þ T cells, macrophages
and neutrophils.
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Figure 7 | Effect of interleukin-18 receptor (IL-18R) on CD4þ and CD8þ T-cell responses. Splenic and renal CD4þ and CD8þ T-cell
apoptosis and activation were assessed by flow cytometric analysis (FACS) in vivo, annexin-V staining (a), CD44 (b), and CD69 expression
(c) and on days 1 and 3, the panels are shown as mean percentages±s.e. (*Po0.05, wild-type (WT) vs. IL-18Ra knockout (KO) mice
on days 1 and 3). **Po0.01. PI, propidium iodide.
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IL-18R deficiency affected the increasing of renal mRNA
pro-inflammatory cytokine and chemokine expressions.
Similarly, in vitro, we demonstrated IL-18R deficiency
affected ConA-stimulated proliferation and pro-inflamma-
tory cytokine production by leukocytes. We also investigated
the intracellular IFN-g secretion on leukocytes from the
spleen and kidney by FACS. Intracellular IFN-g staining on
splenic CD8þ T cells in IL-18Ra-deficient mice was increased
compared with that in WT mice. Thus, IL-18R is associated
with the cytokine pathway in cisplatin-induced AKI.
We also demonstrated the expression of p65 NF-kB and
cleaved caspase-3 in the kidney after cisplatin injection.
Recently, it was reported that phospho NF-kB p65 staining
was markedly increased in the renal tubules of cisplatin-
treated mice.12 Moreover, the expression of multiple pro-
inflammatory cytokines leading to neutrophil-mediated
inflammation has been linked to NF-kB activation.13 IL-18
also modulates the activity of macrophages14 by the
activation of transcription factors including NF-kB.15 We
demonstrated that tubular p65 NF-kB and cleaved caspase-3
expression in IL-18Ra-deficient mice on days 1 and 3 was
increased significantly compared with that in WT mice
(Figure 4). Caspase-3 is known as a major mediator of
apoptosis. Cleaved caspase-3 is activated during cisplatin-
induced renal cell apoptosis as a key step after cisplatin
injection.16 Oxidant stress is also contributed to cisplatin-
induced apoptosis of tubules.17 We investigated the cell
activation (CD44 and CD69 as early activate markers)
and apoptosis (annexin-V) of splenic and renal CD4þ and
CD8þ T cells by FACS and found both activation and
apoptosis to be increased in IL-18Ra-deficient mice. Taken
together, we speculated that CD44 and CD69þ activated
cells on CD4þ and CD8þ T cells through pro-inflamma-
tory cytokines and IL-1/Toll-like receptor-mitogen activated
protein kinase/NF-kB pathway signaling accumulated to
remove the aberrant apoptotic leukocytes (annexin-Vþ
cells) and epithelial cells (caspase-3þ cells) for remodeling.
These results indicated that IL-18Ra affected intracellular
signaling that leads to proliferation, cytokine production, and
apoptosis/nuclear translocation of the NF-kB composed of
p65 and caspase-3 activation.
To confirm our understanding of the functioning of
IL-18R is functioning, we performed the splenocytes adop-
tive transfer and anti-IL-18Ra/b antibody administration.
There was a significant improvement in BUN and acute
tubular necrosis score in IL-18Ra-deficient mice that received
a transfer of splenocytes and a trend toward the deterioration
of renal function in the administration of anti-IL-18Ra/b
antibody.
Inhibition of cytokine signaling by the SOCS family
constitutes a major negative feedback mechanism to
prevent runaway inflammation. The transcription of SOCS
proteins is rapidly upregulated in cells stimulated with
pro-inflammatory cytokines; the SOCS then reduce the
impact of cytokines by interacting with Jaks and by other
mechanisms.18 Furthermore, SOCS1 (ref. 19) and SOCS3
(ref. 20) interfere with IL-1/Toll-like receptor-mitogen
activated protein kinase/NF-kB pathway signaling, the
increase in activity of these kinases in IL-18Ra-deficient cells
may be due to less inhibition resulting from reduced levels of
both SOCS. Recently, it was reported that SOCS1 and SOCS3
mRNA expression and protein production were greatly
reduced in cells with IL-18Ra-deficient mice compared
with cells from WT mice.21 We observed downregulation of
splenic/renal SOCS1 and SOCS3 in IL-18Ra-deficient mice
compared with WT mice. By downregulation of SOCS, pro-
inflammatory cytokines were increased through IL-1/Toll-like
receptor-mitogen activated protein kinase/NF-kB kinases
signaling. Our data support that IL-18Ra may induce,
through SOCS1 and/or SOCS3, anti-inflammatory responses
in addition to pro-injury responses.
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Figure 8 | Expression of suppressors of cytokine signaling
(SOCS)1 and SOCS3 in the kidney on day 3. mRNA (a) and
protein levels (b, c) of SOCS1 and SOCS3 in wild-type (WT),
interleukin-18 receptor (IL-18R)a-deficient (IL-18Ra knockout (KO))
mice on day 3 were assayed by real-time PCR or western blotting.
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898 Kidney International (2012) 82, 892–902
or ig ina l a r t i c l e Y Nozaki et al.: IL-18R and acute kidney injury
MATERIALS AND METHODS
Animals
IL-18Ra-deficient (IL-1Rrp/) mice (C57BL/6) were kindly provided
by Dr S Akira (Osaka University, Osaka, Japan). C57BL/6 mice,
used as a WT control in this study, were purchased from
Shizuoka Laboratory Animal Center (Shizuoka, Japan). All mice
were maintained in our specific pathogen-free animal facility. DNA
samples were extracted from the tail for PCR-based genotyping.
Male mice of 8–10 weeks were used in this study.
Cisplatin treatment of animals
In the majority of experiments, cisplatin was freshly prepared in
saline at 1 mg/ml and injected intraperitoneally in IL-18Ra-deficient
(n¼ 10) and WT mice (n¼ 11) at a dose of 20 mg/kg as previously
described;22 control animals were injected with a comparable
volume of saline. This dose of cisplatin produces severe renal failure
in mice. Animals were culled at days 1 and 3. Blood was collected
from the dorsal aorta in heparinized tubes for measurement of
BUN, serum creatinine, and TNF.
Assessment of renal injury
Tubular injury was assessed in periodic acid-Schiff–stained sections
using a semiquantitative scale23 in which the percentage of cortical
tubules showing epithelial necrosis was assigned a score: 0¼ normal;
1¼o10%; 2¼ 10–25%; 3¼ 26–75%; 4¼475%. The individual
scoring the slides was blinded to the treatment and strain of the
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Figure 9 | Interleukin-18 receptor (IL-18R)a are potent inducers of proliferation response and cytokine production. Effect of
interleukin-18 receptor (IL-18R)a on proliferative response (a) and cytokine production (b). Lymphocytes of spleen and kidney in
IL-18Ra-deficient (IL-18Ra knockout (KO)) and wild-type (WT) mice stimulated with concanavalin A (ConA) (1 mg/ml) for 4 and 48 h on day 1
after cisplatin injection. (c) Splenic and renal CD4þ and CD8þ T cells intracellular cytokine production were assessed by flow cytometric
analysis of IFN-g. The panels are shown as mean values±s.e. (*Po0.05 and ***Po0.005, WT vs. IL-18Ra KO mice). IFN, interferon; TNF, tumor
necrosis factor.
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animal. CD4þ and CD8þ T cells, macrophages, neutrophils, and
Kim-1 were demonstrated by immunoperoxidase staining of
periodate lysine paraformaldehyde-fixed frozen 6-mm-thick kidney
sections, as described previously.24 The numbers of CD4þ and
CD8þ T cells, macrophages, and neutrophils were assessed in 10
fields per slide at a magnification of  400, and results are expressed
as cells per high-power field. Tubular Kim-1 immunostaining was
quantified by counting the number of positively stained tubules
in the cortex in 10 fields per slide at a magnification of  200.
A positive tubule cross-section was defined as having two or more
stained cells. The primary monoclonal antibodies used were rat
monoclonal antibody GK1.5 for CD4þ and 53-6.7 for CD8þ
T cells (Pharmingen, San Diego, CA), for macrophages with F4/80
hybridoma culture supernatant (HB198; American Type Culture
Collection, Manassas, VA), RB6-8C5 for neutrophils (anti-Gr-1;
Pharmingen), and rat monoclonal antibody TIM-1 (R&D Systems,
Minneapolis, MN).
Immunohistochemical analysis of cleaved caspase-3 and
phospho NF-jB p65
Phospho NF-kB p65 and cleaved caspase-3 were identified in
4-mm-thick formalin fixed kidney sections by using rabbit anti-
body recognizing phospho NF-kB p65 and the cleaved form of
caspase-3 (Cell Signaling Technology, Beverly, MA), as described
previously.12,16 The numbers of NF-kB p65-activated and cleaved
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Figure 10 | Effect of splenocyte transfer on renal function and histological damage in cisplatin-induced renal injury on day 3.
Splenocytes were isolated from each mouse on killing and stained with fluorescein isothiocyanate (FITC)-conjugated anti-mouse interleukin-
18 receptor (IL-18R)a antibody and analyzed by flow cytometric analysis (FACS) (a). Blood urea nitrogen (BUN) was measured from blood
samples (b) and tubular necrosis was scored in the outer medulla of the kidney (c) in wild-type (WT), IL-18Ra-deficient (IL-18Ra knockout
(KO)) mice, and IL-18Ra KO mice with splenocyte transfer. Dotted lines represent the mean values from saline-treated mice without cisplatin.
The panels are shown as the mean values±s.e. (*Po0.05, WT vs. IL-18Ra KO mice and IL-18Ra KO mice with splenocyte transfer, and
IL-18Ra KO vs. IL-18Ra KO with splenocyte transfer, ***Po0.005, WT vs. IL-18Ra KO mice). Representative light microscopy of periodic
acid-Schiff (PAS)–stained renal sections after cisplatin injection. Kidneys in WT (d), IL-18Ra KO (e), and IL-18Ra KO mice with splenocyte
transfer mice (f) are shown. Original magnifications  400. Scale bar, 50 mm. ATN, acute tubular necrosis.
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Figure 11 | Effect of anti-interleukin-18 receptor (IL-18R)a and
anti-IL-18Rb antibody administration on renal function and
histological damage in cisplatin-induced renal injury on
day 3. Blood urea nitrogen (BUN) was measured from blood
samples. ATN, acute tubular necrosis; RatIgG, rat immunoglobulin G.
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caspase-3-positive cells, in each section were calculated by counting
the number of positively stained tubules in 10 fields per slide at a
magnification of  400. All tubules in the outer medulla were
assessed for each animal. Large blood vessels and glomeruli were
excluded from the analysis. The individual scoring the slides was
blinded to the treatment.
Real-time PCR analysis
For measurement of intrarenal mRNA expression of TNF, IL-1b,
monocyte chemoattractant protein-1, SOCS1, SOCS3, and 18SrRNA
by FastStart DNA master, Sybr Green I (Applied Biosystems, Foster
City, CA) and IFN-g, IL-4, IL-10, IL-12p40, IL-18, Kim-1, and
18SrRNA by TaqMan gene (Applied Biosystems), as described
previously.24 The sequences of primers and gene database number
are listed in Tables 1 and 2. The relative amount of mRNA was cal-
culated using comparative Ct (DDCt) method. All specific ampli-
cons were normalized against 18SrRNA, which was amplified in the
same reaction as an internal control using commercial reagents
(Applied Biosystems) and was expressed as fold differences relative
to saline-treated control animals.
Urine IL-18 and Kim-1 level excretion
IL-18 (pg/24 h) and Kim-1 (ng/24 h) was measured in the urine
collected from mice after cisplatin injection on days 1 and 3 by
enzyme-linked immunosorbent assay, as described previously.25
Antibodies were rat anti-mouse IL-18 and TIM-1 monoclonal
antibody (R&D Systems), biotinylated goat anti-mouse IL-18 and
TIM-1 (R&D Systems), and streptavidin-horseradish peroxidase
(Chemicon International, Billerica, MA). Plates were developed
using tetramethylbenzidine substrate and optical density was read
at 450 nm.
Isolation of leukocytes from kidney
Previously described methods for leukocyte isolation from murine
kidneys were used.26 Kidneys were digested with 1 mg/ml collage-
nase D (Roche Diagnostics, Penzberg, Germany) and 0.1 mg/ml
DNAse I (Roche Diagnostics) in RPMI 1640 medium supplemented
with 10% fetal calf serum. Viability of the cells was assessed by
Trypan blue staining before single-cell suspensions.
Cell death and activation assay
For assessment of apoptosis and activation by FACS (Becton
Dickinson, Franklin Lakes, NJ), spleens were obtained from mice on
day 1 after cisplatin injection. Apoptosis of CD4þ and CD8þ cells
was assessed by analysis of annexin-V staining (Roche Diagnostics)
and T-cell activation was assessed by analysis of CD44 and CD69
expression on splenic CD4þ and CD8þ cells with allophycocya-
nin-conjugated anti-CD4 (Pharmingen), phycoerythrin-conjugated
anti-CD8 (Pharmingen), and fluorescein isothiocyanate-conjugated
anti-CD44 and CD69 (Pharmingen). After the cells were washed and
resuspended in 0.2 ml of phosphate-buffered saline and propidium
iodide (1 mg/ml; Calbiochem, San Diego, CA) using allophycocya-
nin/Cy-7-conjugated anti-CD4 and allophycocyanin-conjugated
anti-CD8 (Pharmingen). Stained cells were analyzed on a FACSCa-
libur (Becton Dickinson) flow cytometer. Data were analyzed using
CELL-QUEST software (Becton Dickinson).
Western blotting
Proteins were extracted by homogenization of the kidney on day 3
after cisplatin injection in tissue protein extraction reagent (Pierce,
Rockford, IL) to determine SOCS1 and SOCS3, as described
previously.27 Monoclonal anti-b-actin antibody was obtained from
Santa Cruz (St Louis, MO). Anti-mouse SOCS1 and SOCS3
antibody was from Cell Signaling Technology. Peroxidase-conju-
gated goat immunoglobulin G was from Santa Cruz.
Proliferation assay and measurement of cytokines
On day 1, the spleen was removed after cisplatin injection, and
single-cell suspensions were made in RPMI 1640 medium
supplemented with 10% fetal calf serum and adjusted to 2.5 106
cells per well. Spleen cells were plated in triplicate in a flat-bottomed
96-well plate and stimulated with ConA (1 mg/ml) or medium alone
for 6 and 48 h, according to the previous report.28 Proliferation was
assessed by CellTiter 96 AQueous One Solution Reagent (Promega,
Madison, WI) and cytokine concentrations (IL-1b, TNF, IFN-g,
IL-12p40, and IL-10) in the supernatant were determined by
enzyme-linked immunosorbent assay, as described previously.28
Splenocyte adoptive transfer
IL-18Ra-deficient mice received an adoptive transfer of splenocytes
from WT mice. Splenocytes that were collected from C57BL/6 WT
mice were minced on a nylon mesh, as described previously.29
Approximately 5 106 spleen cells were injected intraperitoneally
into each IL-18Ra-deficient mouse 3 weeks before cisplatin
(20 mg/kg) injection. IL-18Ra-deficient (n¼ 5), WT mice (n¼ 8),
and the mice received a transfer of splenocytes (n¼ 10) were
culled on day 3. To confirm T-cell reconstitution in IL-18Ra-
deficient mice, splenocytes were analyzed for a population of
IL-18R-positive cells by FACS. Fluorescein isothiocyanate-
conjugated IL-18Ra and immunoglobulin G1 were purchased
from R&D Systems.
Administration of IL-18Ra and b monoclonal antibody
Monoclonal antibody to IL-18Ra (R&D Systems), IL-18Rb
(Pharmingen), or rat immunoglobulin G as a control was
administered (400 mg) 1 day before cisplatin (20 mg/kg) adminis-
tration. Mice (each group, n¼ 5) were culled on day 3.
Table 1 | Primer sequences for analysis of mRNA expression
Forward primer Reverse primer
18SrRNA 50-GTAACCCGTTGAACCCCATTC-30 50-GCCTCACTAAACCATCCAATCG-30
IL-1b 50-TGTAATGAAAGACGGCACACC-30 50-TCTTCTTTGGGTATTGCTTGG-30
TNF-a 50-CGATCACCCCGAAGTTCAGTA-30 50-GGTGCCTATGTCTCAGCCTCTT-30
CCL2/MCP-1 50-AAAAACCTGGATCGGAACCAA-30 50-CGGGTCAACTTCACATTCAAAG-30
SOCS1 50-GTGGTTGTGGAGGGTGAGATG-30 50-GGGATGAGGTCTCCAGCCA-30
SOCS3 50-CCTTTCTTATCCGCGACAGC-30 50-CGCTCAACGTGAAGAAGTGG-30
Abbreviations: CCL2/MCP-1, monocyte chemoattractant protein-1; IL, interleukin;
SOCS, suppressors of cytokine signaling; TNF, tumor necrosis factor.
Table 2 | Gene database number for analysis of mRNA
expression
Gene database number
18SrRNA NM_026744.3
IFN-g NM_008337.3
IL-4 NM_021283.2
IL-10 NM_010548.1
IL-12p40 NM_008352.2
IL-18 NM_008360.1
Kim-1 NM_134248.1
Abbreviations: IFN, interferon; IL, interleukin.
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Statistical analysis
Results are expressed as mean±s.e.m. Unpaired t-test was used for
statistical analysis (GrandPad Prism; GraphPad Software, San Diego,
CA). Differences were considered to be statistically if Po0.05.
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